Vanda's HETLIOZ Shows Promise in Phase III Trial for Delayed Sleep-Wake Disorder
Event summary
- Vanda Pharmaceuticals' Phase III trial of HETLIOZ for Delayed Sleep-Wake Phase Disorder (DSWPD) met its primary endpoint, shifting sleep onset 37.1 minutes earlier than placebo.
- 60% of HETLIOZ-treated patients advanced sleep timing by at least 30 minutes, compared to 15% on placebo.
- Vanda plans to submit a supplemental New Drug Application (sNDA) for HETLIOZ in DSWPD, potentially making it the first FDA-approved treatment for the condition.
- The trial enrolled 43 patients across 26 clinical sites in the US and Europe over five years.
The big picture
Vanda's positive Phase III results for HETLIOZ in DSWPD mark a strategic expansion for the drug, which is already approved for two other circadian disorders. If approved, HETLIOZ could become the first FDA-approved treatment for DSWPD, addressing a significant unmet need in sleep medicine. The move underscores Vanda's focus on circadian rhythm disorders and its potential to dominate this niche therapeutic area.
What we're watching
- Regulatory Pathway
- Whether the FDA will approve HETLIOZ for DSWPD, given its existing approvals for other circadian disorders.
- Market Opportunity
- The potential market size for DSWPD treatment, with an estimated 0.5 to 4.1 million affected adults in the US.
- Competitive Landscape
- How Vanda's move could position HETLIOZ as a leading treatment for circadian sleep disorders.